ImmunityBio, Inc.
IBRX
Rangering i aksjer
#2231
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Aksjekurs
$8.55
Sist synkronisert: 2026-10-19
Markedsverdi
$9.06B
Endring (1 dag)
-6.84%
Endring (1 år)
249.08%
Land
US
Handel ImmunityBio, Inc. (IBRX)
Kategori
Healthcare
P/S-forhold for ImmunityBio, Inc. (IBRX)
P/S-forhold per October 2026 TTM: 63.35
Ifølge ImmunityBio, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 63.35. Ved slutten av 2023 hadde selskapet et P/S-forhold på 4.11K.
P/S-historikk for ImmunityBio, Inc. fra 2013 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 63.35 | -47.67% |
| 2024 | 121.07 | -97.05% |
| 2023 | 4.11K | -51.41% |
| 2022 | 8.45K | 233.41% |
| 2021 | 2.53K | -69.99% |
| 2020 | 8.44K | 1,180.13% |
| 2019 | 659.51 | -91.78% |
| 2018 | 8.02K | -74.57% |
| 2017 | 31.54K | -26.15% |
| 2016 | 42.71K | 78.26% |
| 2015 | 23.96K | 40.43% |
| 2014 | 17.06K | -62.92% |
| 2013 | 46.02K | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -84.18% |
US
|
|
| 40.55 | -35.99% |
US
|
|
| 3.96 | -93.75% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -83.98% |
NL
|
